The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis

• Thrombosis as main complication of CHD, cause of morbidity and mortality in patients with T2DM.
• DM some coagulation abnormalities occur, that may result in a thrombogenic propensity.
• Aspirin as an anti-platelet agent uses for the prevention and treatment of atherothrombotic disorders.
• Up to 20% of vascular events are attributable to a failure of ASA to suppress platelet aggregation.
• The consumption of antioxidant imparts anti-thrombotic effects similar to the action of aspirin.

Thrombosis as the main complication of coronary heart disease (CHD) represents the primary cause of morbidity and mortality in patients with diabetes mellitus (DM). In the course of diabetes mellitus some coagulation abnormalities occur, that may result in a thrombogenic propensity.Aspirin (ASA) as a platelet-inhibiting agent through inactivation of Cyclooxygenase-1 (COX-1) is mostly used for the prevention and treatment of atherothrombotic disorders. ASA inhibits the COX-1 enzyme and therefore blocks platelet thromboxane A2 (TXA2) synthesis. However, some of the serious vascular events in high-risk vascular patients are attributable to a failure of ASA to suppress platelet aggregation. The consumption of antioxidant or antioxidant rich foods such as vitamin C, E, and polyphenols might impart anti-thrombotic and cardiovascular protective effects via their inhibition of platelet hyper-activation or aggregation similar to the action of aspirin.This review will discuss the risk of thrombosis in diabetes, what aspirin resistance means, and the effectiveness of antioxidant therapy in the prevention and possible treatment of atherothrombotic disorders.